LCM
IBRX icon

Laurion Capital Management’s ImmunityBio IBRX Stock Holding History

Laurion Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,069
Closed -$158K – 440
2024
Q2 		$158K Buy
+25,069
New +$165K ﹤0.01% 490
2020
Q1 		– Sell
-17,200
Closed -$65K – 907
2019
Q4 		$65K Buy
+17,200
New +$29.3K ﹤0.01% 844
2016
Q2 		– Sell
-19,600
Closed -$161K – 919
2016
Q1 		$161K Buy
+19,600
New +$185K ﹤0.01% 702

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laurion Capital Management's IBRX Position: Q3 2024 in Review

Laurion Capital Management sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 25,069 shares — an estimated $158K sold.

Laurion Capital Management first reported a position in IBRX in Q1 2016 and held it in 3 quarters. The position peaked at $161K in Q1 2016. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Laurion Capital Management reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 25,069 ImmunityBio shares in Q3 2024, an estimated $158K.
  • Laurion Capital Management first reported a position in ImmunityBio in Q1 2016 and held it in 3 quarters.
  • Laurion Capital Management's ImmunityBio position peaked at $161K in Q1 2016.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.